Brind.

The FDA approved the Brekiya® autoinjector from Amneal Pharmaceuticals on August 5, 2025.

1 report, 1 independent Updated Aug 5

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Amneal Pharmaceuticals, Inc.

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Amneal Pharmaceuticals, Inc.
American publicly traded generics and specialty pharmaceutical company

Nothing else this week.

Related events

Inventiva seeks FDA approval for lanifibranor in the U.S. market.Sep 2

Coverage

Newest first; wire copies grouped

Aug 5GlobeNewswireAmneal Reports Second Quarter 2025 Financial Results ‒ Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 ‒ ‒ Adjusted EBITDA of $184 million; Adju